pneumonia

View All

Airway Management Devices Market Insights
Airway Management Devices: Charting the Evolving Market Trends and Key Innovations

Technological evolution has significantly transformed Airway Management Devices in recent years, ushering in a new era of efficiency, precision, and patient safety. Advances in materials, design, and manufacturing processes have led to the development of more sophisticated devices. Moreover, the incorporation of hi...

Find More

driving-factors-for-ards-prevalence
Rising Acute Respiratory Distress Syndrome (ARDS) Prevalence Posing a Major Public Health Concern

The acute respiratory distress syndrome (ARDS) prevalence is increasing every year; it is estimated that in the United States alone, about 190K Americans are diagnosed with ARDS each year. Prior to the COVID-19 global pandemic, more than 700K individuals in the US and 2 million cases globally developed ARDS from tr...

Find More

most-deadly-Infectious-diseases-in-the-world
Infectious Diseases That Possess Significant Challenge To Humans Health

Infectious diseases or communicable diseases are one of the leading causes of death worldwide. These diseases are spread by pathogenic microorganisms, such as bacteria, viruses, parasites, or fungi. Infectious diseases possess greater risk as these diseases can easily transfer from human to human or by other modes....

Find More

Cytomegalovirus-Infection-Market
The Increasing Global Burden of Cytomegalovirus Seroprevalence

Cytomegalovirus (CMV) is a common herpes virus, and approximately 50 to 80 per cent of the adult US population has had a CMV infection by the time they turn 40. Once the virus infects an individual, it stays in their bodies in dormant form.  The estimates by DelveInsight suggest that the total number of dia...

Find More

covid-news
In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit

Eli Lilly has announced to begin clinical trials of rheumatoid arthritis drug Olumiant to treat COVID-19 patients.  The company plans to explore the anti-inflammatory responses that were witnessed in rheumatoid arthritis patients, and how the drug – Olumiant – an oral JAK1/JAK2 inhibitor – might help in cur...

Find More

Pharma-News
Thermo’s investment; Biohaven’s vazegepant Phase III trial; Cumberland’s aid

Thermo Fisher Scientific has announced to invest a hefty amount worth USD 800 Million across pharma manufacturing and services. The company plans to expand its capabilities in pharma manufacturing and services in the coming two years, with USD 475 Million reserved for 2020.  The company has been acquirin...

Find More

Notizia 11 june
Notizia

Lilly tests the efficacy of Tirzepatide-a novel dual GIP, GLP-1 agonist Eli Lilly is planning to test its diabetes drug Tirzepatide in a phase 2b Non-Alcoholic Steatohepatitis (NASH) trial. Tirzepatide, also known as LY3298176, has been excellent in reducing body weight and blood sugar in patients with poorly co...

Find More